Lyell Immunopharma Inc (LYEL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$15.00-2.79%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · LYEL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 400.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -51.6% |
Growth built into the price is above our model estimate.
The price assumes 452.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers
LYEL — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-11-04
Unregistered Sales of Equity Securities. On November 3, 2026, Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors an aggregate of 7,428,040 shares (“Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $10.77 per Sha…
Why it matters: The data can show whether the new dose and safety plan work in colorectal cancer. The FDA meeting can clarify the next trial step.
Watch forNew trial data show patients treated with the LyFE process, and Lyell reports a recommended Phase 2 dose and an FDA meeting.
Also watch forThe data show serious safety problems, no workable dose, or the planned 2027 FDA meeting is delayed.
Why it matters: The update tests ronde-cel in large B-cell lymphoma. The trial's main measure is tumor response and how long it lasts.
Watch forThe update shows tumor responses and how long they lasted in the PiNACLE 3L+ group. It reports no new safety concern.
Also watch forThe update shows weak tumor responses, short response length, or a serious new safety concern.
Why it matters: The report can show whether spending stays in line with the cash runway plan. Lyell reported a $44.8 million net loss in Q2.
Worry ifThe report shows a quarterly net loss above $44.8 million and a shorter cash runway than Q3 2027.
Less concerning ifThe report shows a quarterly net loss at or below $44.8 million and keeps the runway through Q3 2027.
Why it matters: This Phase 3 trial tests ronde-cel against two approved CAR T-cell treatments. Its main measure is how long patients live without key disease events.
Watch forThe second-half 2026 update reports that more patients joined the trial. It also reports progress toward measuring event-free survival.
Also watch forThe update reports a pause, major enrollment delay, or a change to the event-free survival trial plan.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$265 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $810 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,054 loss on $10,000 · 80.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Cash fell from $261 million in March to $228 million in June. A faster decline could shorten the stated runway.
Worry ifAt the next report, cash, cash equivalents, and marketable securities fall below $228 million. Or Lyell cuts its runway estimate from Q3 2027.
Less concerning ifCash remains at or above $228 million, and Lyell keeps its runway estimate through Q3 2027.